Adjunctive therapies and immunomodulating agents for severe influenza

Influenza and other Respiratory Viruses

Volumn 7, Issue SUPPL.3, 2013, Pages 52-59

  Hui, David S C ^a   Lee, Nelson ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjunctive therapies; Immunomodulating agents; Influenza; Severe acute respiratory syndrome; Viral infections

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; AZITHROMYCIN; CELECOXIB; CLARITHROMYCIN; CORTICOSTEROID; DEXAMETHASONE; GEMFIBROZIL; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MACROLIDE; MESALAZINE; OSELTAMIVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; POLYMYXIN B; ROSIGLITAZONE; ROSUVASTATIN; SIVELESTAT; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; ASTHMA; AVIAN INFLUENZA; BACTEREMIA; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; CYTOKINE STORM; DISEASE SEVERITY; DRUG MEGADOSE; HEMOPERFUSION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA A (H5N1); LOW DRUG DOSE; NONHUMAN; PANDEMIC INFLUENZA; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEASONAL INFLUENZA; SEPSIS; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS PNEUMONIA; WHEEZING;

ADJUNCTIVE THERAPIES; IMMUNOMODULATING AGENTS; INFLUENZA; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL INFECTIONS;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887518747     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12171     Document Type: Review

References (72)

1. Chan PK. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002; 34(Suppl. 2):S58-S64.
2. Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-619.
3. Lee N, Hui DS, Wu A, Chan P et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994.
4. WHO Writing Committee. Clinical aspects of pandemic influenza A (H1N1) 2009. N Engl J Med 2010; 362:1708-1719.
5. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.
6. Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237-247.
7. To KK, Hung IF, Li IW et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-859.
8. Lee N, Choi KW, Chan PK et al. Outcomes of adults hospitalized with severe influenza. Thorax 2010; 65:510-515.
9. Wong CK, Lam CW, Wu AK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103.
10. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS ONE 2012; 7:e47926.
11. Lee N, Hui DS. Dexamethasone in community-acquired pneumonia. Lancet 2011; 378:979-980.
12. Lee N, Chan PK, Hui DS et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
13. Kudo K, Takasaki J, Manabe T et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS ONE 2012; 7:e32280.
14. Martin-Loeches I, Lisboa T, Rhodes A et al. ESICM H1N1 Registry Contributors. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37:272-283.
15. Brun-Buisson C, Richard JC, Mercat A et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-1206.
16. Kim SH, Hong SB, Yun SC et al. Korean Society of Critical Care Medicine H1N1 Collaborative. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:1207-1214.
17. Han K, Ma H, An X et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53:326-333.
18. Diaz E, Martin-Loeches I, Canadell L et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012; 64:311-318.
19. Linko R, Pettilä V, Ruokonen E et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand 2011; 55:971-979.
20. Tang NL, Chan PK, Wong CK et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005; 51:2333-2340.
21. Tse GM, To KF, Chan PK et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57:260-265.
22. Lee N, Chan AK, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304-309.
23. Chen RC, Tang XP, Tan SY et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006; 129:1441-1452.
24. Wang H, Ding Y, Li X et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349:507-508.
25. Yap FH, Gomersall CD, Fung KS et al. Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis 2004; 39:511-516.
26. Griffith JF, Antonio GE, Kumta SM et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235:168-175.
27. Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004; 59:602-608.
28. Lat A, Bhadelia N, Miko B et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971-973.
29. Buckingham SC, Jafri HS, Bush AJ et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185:1222-1228.
30. Gustafson LM, Proud D, Hendley JO et al. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996; 97:1009-1014.
31. Puhakka T, Mäkelä MJ, Malmström K et al. The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol 1998; 101:726-731.
32. Domachowske JB, Bonville CA, Ali-Ahmad D et al. Glucocorticoid administration accelerates mortality of pneumovirus infected mice. J Infect Dis 2001; 184:1518-1523.
33. Luke T, Kilbane E, Jackson J, Hoffman S. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
34. Soo YO, Cheng Y, Wong R et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-678.
35. Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-46.
36. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1451.
37. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:510-519.
38. Hung IF, To KK, Lee CK et al. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 2013; 144:464-473.
39. Geiler J, Michaelis M, Naczk P et al. N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 2010; 79:413-420.
40. Lai KY, Ng WY, Osburga Chan PK et al. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010; 152:687-688.
41. Garozzo A, Tempera G, Ungheri D et al. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 2007; 20:349-354.
42. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 2011; 82:548-555.
43. Takeda S, Munakata R, Abe S et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intens Care Med 2010; 36:906-907.
44. Patel P, Nadwani V, Vanchiere J et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza-An associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med 2011; 12:e87-e89.
45. Hong DK, Tremoulet AH, Burns JC et al. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza A virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2011; 30:67-69.
46. Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect 2011; 44:319-322.
47. Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K. Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 2012; 6:245-247.
48. Lew TW, Kwek TK, Tai D et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290:374-380.
49. Chong PY, Chui P, Ling AE et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128:195-204.
50. Umapathi T, Kor AC, Venketasubramanian N et al. Large artery ischemic stroke in severe acute respiratory distress syndrome (SARS). J Neuro 2004; 251:1227-1231.
51. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129-142.
52. Radigan KA, Urich D, Misharin AV et al. The effect of rosuvastatin in a murine model of influenza A infection. PLoS ONE 2012; 7:e35788.
53. Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol 2012; 7:801-818.
54. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS ONE 2009; 4:e8087.
55. Brett SJ, Myles P, Lim WS et al. Influenza Clinical Information Network (FLU-CIN). Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS ONE 2011; 6:e18120.
56. Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:13-19.
57. Makris D, Manoulakas E, Komnos A et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011; 39:2440-2446.
58. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29:91-97.
59. Yamaya M, Shinya K, Hatachi Y et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010; 333:81-90.
60. Viasus D, Paño-Pardo JR, Cordero E et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62:193-199.
61. Ishii H, Komiya K, Yamagata E et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 2012; 64:343-345.
62. Martín-Loeches I, Bermejo-Martin JF, Vallés J et al. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013; 39:693-702.
63. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890.
64. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:2965-2968.
65. Bauer CM, Zavitz CC, Botelho FM et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS ONE 2010; 5:e13251.
66. Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106:5306-5311.
67. Pitocco D, Giubilato S, Zaccardi F et al. Pioglitazone reduces monocyte activation in type 2 diabetes. Acta Diabetol 2009; 46:75-77.
68. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi Viruses 2010; 4:307-311.
69. Carey MA, Bradbury JA, Seubert JM et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005; 175:6878-6884.
70. Carey MA, Bradbury JA, Rebolloso YD et al. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS ONE 2010; 5:e11610.
71. Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res 2011; 91:330-334.
72. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:8091-8096.